Theravance Biopharma (TBPH) Cash from Investing Activities (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of Cash from Investing Activities data on file, last reported at $52.6 million in Q1 2026.

• On a quarterly basis, Cash from Investing Activities rose 71.69% year-over-year to $52.6 million in Q1 2026; TTM through Mar 2026 was -$83.3 million, a 421.86% decrease from a year earlier, with the FY2025 full-year figure at -$105.3 million, down 957.08% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $52.6 million, up from $588000.0 in the prior quarter.
• Over the last five years, Cash from Investing Activities for TBPH reached as high as $52.6 million in Q1 2026 and fell as low as -$100.2 million in Q3 2025.
• Historically, Cash from Investing Activities has averaged -$837000.0 across 5 years, with a median of $588000.0 in 2025.
• On a YoY basis, Cash from Investing Activities climbed as much as 2416.99% in 2024 and fell as far as 82752.38% in 2024.
• Year by year, Cash from Investing Activities stood at $39.2 million in 2022, then plunged by 101.73% to -$677000.0 in 2023, then surged by 2416.99% to $15.7 million in 2024, then slumped by 96.25% to $588000.0 in 2025, then soared by 8844.39% to $52.6 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were $52.6 million in Q1 2026, $588000.0 in Q4 2025, and -$100.2 million in Q3 2025.